MyoKardia, Inc. (MYOK) EPS Estimated At $-0.65

MyoKardia, Inc. (NASDAQ:MYOK) Logo

Analysts expect MyoKardia, Inc. (NASDAQ:MYOK) to report $-0.65 EPS on May, 9 after the close.They anticipate $0.15 EPS change or 30.00 % from last quarter’s $-0.5 EPS. After having $-0.39 EPS previously, MyoKardia, Inc.’s analysts see 66.67 % EPS growth. The stock increased 3.20% or $1.49 during the last trading session, reaching $48.07. About 108,281 shares traded. MyoKardia, Inc. (NASDAQ:MYOK) has declined 14.35% since May 8, 2018 and is downtrending. It has underperformed by 18.72% the S&P500.

MyoKardia, Inc., a clinical stage biopharmaceutical company, engages in discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. The company has market cap of $2.21 billion. The Company’s lead product candidate is MYK-461, an orally-administered small molecule that is in Phase II clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy . It currently has negative earnings. The firm also develops MYK-491, an orally-administered small molecule that treats genetic dilated cardiomyopathy (DCM) by restoring normal contractility in the diseased DCM heart.

More notable recent MyoKardia, Inc. (NASDAQ:MYOK) news were published by: which released: “Did Hedge Funds Drop The Ball On On Dana Incorporated (DAN) ? – Yahoo Finance” on April 30, 2019, also with their article: “MyoKardia (MYOK) Reports Q3 Loss, Tops Revenue Estimates –” published on November 07, 2018, published: “A Peek Into The Markets: US Stock Futures Climb Ahead Of Economic Data – Benzinga” on March 26, 2019. More interesting news about MyoKardia, Inc. (NASDAQ:MYOK) were released by: and their article: “MyoKardia (MYOK) Announces Clinical Trial Results from Phase 2 PIONEER-HCM Study of Mavacamten Published in Annals of Internal Medicine –” published on April 30, 2019 as well as‘s news article titled: “MyoKardia Reports Second Quarter 2018 Financial Results Nasdaq:MYOK – GlobeNewswire” with publication date: August 08, 2018.

MyoKardia, Inc. (NASDAQ:MYOK) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.